The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and Epoetin
Open accessAbstract
BackgroundIn patients with end-stage renal dis- ease, anemia develops as a result of erythropoietin deficiency, and recombinant human erythropoietin (epoetin) is prescribed to correct the anemia partially.We examined the risks and benefits of normalizing the hematocrit in patients with cardiac disease who were undergoing hemodialysis. MethodsWe studied 1233 patients with clinical ev- idence of congestive heart failure or ischemic heart disease who were undergoing hemodialysis: 618 patients were assigned to receive increasing doses of epoetin to achieve and maintain a hematocrit of 42 percent, and 615 were assigned to receive doses of epoetin sufficient to maintain a hematocrit of 30 percent throughout the study.The median duration of treatment was 14 months.The primary end point was the length of time to death or a first nonfatal myocardial infarction. ResultsAfter 29 months, there were 183 deaths and 19 first nonfatal myocardial infarctions among the patients in the normal-hematocrit group and 150 deaths and 14 nonfatal myocardial infarctions among those in the low-hematocrit group (risk ratio for the normal-hematocrit group as compared with the lowhematocrit group, 1.3; 95 percent confidence interval, 0.9 to 1.9).Although the difference in event-free survival between the two groups did not reach the prespecified statistical stopping boundary, the study was halted.The causes of death in the two groups were similar.The mortality rates decreased with increasing hematocrit values in both groups.The patients in the normal-hematocrit group had a decline in the adequacy of dialysis and received intravenous iron dextran more often than those in the low-hematocrit group. ConclusionsIn patients with clinically evident congestive heart failure or ischemic heart disease who are receiving hemodialysis, administration of epoetin to raise their hematocrit to 42 percent is not recommended.(N
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The acute hemodynamic responses of EPO administration may result in impaired perfusion/oxygen supply to the tissues and contribute to acute adverse events such as enhanced PLT aggregation, thromboembolism, and myocardial ischemia (17, 45).”
From Red Blood Cell Function and Dysfunction: Redox Regulation, Nitric Oxide Metabolism, Anemia (2017) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
MCHORNEY, C. A., JOHNE, W., & ANASTASIAE, R. (1993) · Medical Care · doi:10.1097/00005650-199303000-00006 · Cited by 6,681
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Salonen, J. T., Nyyssönen, K., Korpela, H., Tuomilehto, J., Seppänen, R., & Salonen, R. (1992) · Circulation · doi:10.1161/01.cir.86.3.803 · Cited by 1,284
IRON AND THE SEX DIFFERENCE IN HEART DISEASE RISK
Sullivan, J. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92463-6 · Cited by 969
Eschbach, J. W., Abdulhadi, M. H., Browne, J. K., Delano, B. G., Downing, M. R., Egrie, J. C., Evans, R. W., Friedman, E. A., Graber, S. E., Haley, N. R., et al. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-12-992 · Cited by 795
Self-citationImpact of left ventricular hypertrophy on survival in end-stage renal disease
Silberberg, J. S., Barré, P. E., Prichard, S. S., & Sniderman, A. D. (1989) · Kidney International · doi:10.1038/ki.1989.192 · Cited by 780
The Quality of Life of Hemodialysis Recipients Treated With Recombinant Human Erythropoietin
Evans, R. W. (1990) · JAMA · doi:10.1001/jama.263.6.825 · Cited by 401
Research works printed but not linked: 8
- Pascual J, 1991, Clin Nephrol, 35, 280
- Eschbach JW, 1993, J Am Soc Nephrol, 4, 425
- Collins A, 1994, J Am Soc Nephrol, 5, 439
- Nissenson AR, 1996, J Am Soc Nephrol, 7, 1459
- Barany P, 1996, J Am Soc Nephrol, 7, 1472
- Benz RL, 1996, J Am Soc Nephrol, 7, 1473
- Hoen B, 1995, Nephrol Dial Transplant, 10, 377
- Collins A, 1997, J Am Soc Nephrol, 8, 190A
Cited by
Sorted by citations
Items 301–400 of 1,000
Influence of target hemoglobin in dialysis patients on morbidity and mortality
Collins, A. J. (2002) · Kidney International · doi:10.1046/j.1523-1755.61.s80.9.x · Cited by 76
The Normal Hematocrit Study — Follow-up
Besarab, A., Goodkin, D. A., & Nissenson, A. R. (2008) · New England Journal of Medicine · doi:10.1056/nejmc076523 · Cited by 76
Self-citationMOIST, L. M., Troyanov, S., White, C. T., Wazny, L. D., Wilson, J.-A. S., McFarlane, P., Harwood, L., Sood, M. M., Soroka, S., Bass, A. S., et al. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.08.001 · Cited by 75
Ku, E., Glidden, D. V., Johansen, K. L., Sarnak, M. J., Tighiouart, H., Grimes, B. A., & Hsu, C. (2014) · Kidney International · doi:10.1038/ki.2014.376 · Cited by 75
Hemoglobin Concentration and Risk of Incident Stroke in Community-Living Adults
Panwar, B., Judd, S. E., Warnock, D. G., McClellan, W. M., Booth, J. N., Muntner, P., & Gutiérrez, O. M. (2016) · Stroke · doi:10.1161/strokeaha.116.013077 · Cited by 75
Evans, M., Bower, H., Cockburn, E., Jacobson, S. H., Barany, P. F., & Carrero, J. J. (2020) · Clinical Kidney Journal · doi:10.1093/ckj/sfaa054 · Cited by 74
Kobayashi, H., Minatoguchi, S., Yasuda, S., Bao, N. D., Kawamura, I., Iwasa, M., Yamaki, T., Sumi, S., Misao, Y., Ushikoshi, H., et al. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn154 · Cited by 74
Manns, B., Stevens, L., Miskulin, D. C., Owen, W. F., Winkelmayer, W. C., & Tonelli, M. A. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00877.x · Cited by 74
Gejyo, F., Saitō, A., Akizawa, T., Akiba, T., Sakai, T., Suzuki, M., Nishi, S., Tsubakihara, Y., Hirakata, H., & Bessho, M. (2004) · Therapeutic Apheresis and Dialysis · doi:10.1111/j.1774-9987.2004.00199.x · Cited by 74
Haase, V. H., Chertow, G. M., Block, G. A., Pérgola, P. E., deGoma, E. M., Khawaja, Z., Sharma, A. K., Maroni, B. J., & McCullough, P. A. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy055 · Cited by 73
Anemia as a risk factor for chronic kidney disease
Iseki, K., & Kohagura, K. (2007) · Kidney International · doi:10.1038/sj.ki.5002481 · Cited by 73
Li, S., Foley, R. N., & Collins, A. J. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00584.x · Cited by 73
Cardiovascular risk in patients with mild renal insufficiency
Mann, J. F. E., Gerstein, H. C., Dulau-Florea, I., & Lonn, E. (2003) · Kidney International · doi:10.1046/j.1523-1755.63.s84.27.x · Cited by 73
Szczech, L. A. M., Barnhart, H. X., Sapp, S. K., Felker, G. M., Hernandez, A. F., Reddan, D. N., Califf, R. M., Inrig, J. K., Patel, U. D., & Singh, A. K. (2009) · Kidney International · doi:10.1038/ki.2009.415 · Cited by 72
Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients
Ngo, K., Kotecha, D., Walters, J. A., Manzano, L., Palazzuoli, A., van Veldhuisen, D. J., & Flather, M. D. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007613.pub2 · Cited by 72
Levin, A., Djurdjev, O., Duncan, J., Rosenbaum, D., & Werb, R. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfi209 · Cited by 72
ESRD in Australia and New Zealand at the end of the millennium: A report from the ANZDATA registry
McDonald, S. P., Russ, G. R., Kerr, P. G., & Collins, J. F. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.36943 · Cited by 72
Erythropoietin for End-Stage Renal Disease
Adamson, J. W., & Eschbach, J. W. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390910 · Cited by 72
Model Predictive Control of Erythropoietin Administration in the Anemia of ESRD
Gawęda, A. E., Jacobs, A. A., Aronoff, G. R., & Brier, M. E. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.10.003 · Cited by 71
Cardiovascular disease and chronic kidney disease: Insights and an update
Best, P. J. M., Reddan, D. N., Berger, P. B., Szczech, L. A. M., McCullough, P. A., & Califf, R. M. (2004) · American Heart Journal · doi:10.1016/j.ahj.2004.04.011 · Cited by 71
Joffe, M. M., Small, D. S., & Hsu, C. (2007) · Cited by 71
Stoumpos, S., Crowe, K., Sarafidis, P. A., Barratt, J., Bolignano, D., Vecchio, L. D., Małyszko, J., Więcek, A., Ortíz, A., & Cozzolino, M. G. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae075 · Cited by 70
Asano, M., Thumma, J. R., Oguchi, K., Pisoni, R. L., Akizawa, T., Akiba, T., Fukuhara, S., Kurokawa, K., Ethier, J. H., Saran, R., et al. (2013) · Nephron Clinical Practice · doi:10.1159/000353733 · Cited by 70
Iron Metabolism, Iron Deficiency, Thrombocytosis, and the Cardiorenal Anemia Syndrome
Besarab, A., Hörl, W. H., & Silverberg, D. S. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-s1-22 · Cited by 69
Self-citationMeta-Analysis of Biochemical and Patient-Level Effects of Calcimimetic Therapy
Strippoli, G. F., Palmer, S. C., Tong, A., Elder, G. J., Messa, P., & Craig, J. C. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.01.015 · Cited by 69
Brazg, R. L., Klaff, L. J., & Parkin, C. G. (2013) · Journal of Diabetes Science and Technology · doi:10.1177/193229681300700117 · Cited by 68
Hemoglobin Variability Does Not Predict Mortality in European Hemodialysis Patients
Eckardt, K., Kim, J. D., Kronenberg, F., Aljama, P., Anker, S. D., Canaud, B., Molemans, B., Stenvinkel, P., Schernthaner, G., Ireland, E., et al. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009101017 · Cited by 68
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
Garrick, R. (2010) · Yearbook of Medicine · doi:10.1016/s0084-3873(10)79646-2 · Cited by 68
Traditional and Nontraditional Cardiovascular Risk Factors in Chronic Kidney Disease
Vlagopoulos, P. T., & Sarnak, M. J. (2005) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.11.003 · Cited by 67
Cardiovascular risk and management in chronic kidney disease
Rucker, D., & Tonelli, M. A. (2009) · Nature Reviews Nephrology · doi:10.1038/nrneph.2009.42 · Cited by 67
Ford, B. A., Eby, C. S., Scott, M. G., & Coyne, D. W. (2010) · Kidney International · doi:10.1038/ki.2010.254 · Cited by 67
Goodkin, D. A., Fuller, D. S., Robinson, B. M., Combe, C., Fluck, R., Mendelssohn, D. C., Akizawa, T., Pisoni, R. L., & Port, F. K. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010020173 · Cited by 67
Self-citationDefining and Estimating Intervention Effects for Groups that will Develop an Auxiliary Outcome
Joffe, M. M., Small, D., & Hsu, C.-Y. (2007) · Statistical Science · doi:10.1214/088342306000000655 · Cited by 67
Nangaku, M., Hamano, T., Akizawa, T., Tsubakihara, Y., Nagai, R., Okuda, N., Kurata, K., Nagakubo, T., Jones, N. P., Endo, Y., et al. (2021) · American Journal of Nephrology · doi:10.1159/000513103 · Cited by 66
Swaminathan, S., Mor, V., Mehrotra, R., & Trivedi, A. N. (2012) · Health Affairs · doi:10.1377/hlthaff.2012.0368 · Cited by 65
Baseline Characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
Pfeffer, M. A., Burdmann, E. A., Chen, C.-Y., Cooper, M. E., de Zeeuw, D., Eckardt, K., Ivanovich, P. T., Kewalramani, R., Levey, A. S., Lewis, E. F., et al. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.04.008 · Cited by 65
Vecchio, L. D., & Locatelli, F. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1182494 · Cited by 65
Therapeutic targeting of the HIF oxygen-sensing pathway: Lessons learned from clinical studies
Haase, V. H. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.05.004 · Cited by 65
Erythropoietin mimics ischemic preconditioning
Baker, J. E. (2005) · Vascular Pharmacology · doi:10.1016/j.vph.2005.02.004 · Cited by 65
Anaemia in CKD—treatment standard
Macdougall, I. C. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad250 · Cited by 64
Suki, W. N. (2007) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2007.10.019 · Cited by 64
Erythropoietin in Brain Development and Beyond
Alnaeeli, M., Wang, L., Piknova, B., Rogers, H. M., Li, X., & Noguchi, C. T. (2012) · Anatomy Research International · doi:10.1155/2012/953264 · Cited by 64
FGF-23: the rise of a novel cardiovascular risk marker in CKD
Heine, G. H., Seiler, S., & Fliser, D. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs259 · Cited by 64
Serum Erythropoietin in Heart Failure Patients Treated with ACE-Inhibitors or AT1 Antagonists
Chatterjee, B., Nydegger, U. E., & Mohaçsi, P. (2000) · European Journal of Heart Failure · doi:10.1016/s1388-9842(00)00110-0 · Cited by 64
Singh, A. K. (2010) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e32833cf1d6 · Cited by 63
Influence of the cyclic variation of hydration status on hemoglobin levels in hemodialysis patients
Bellizzi, V., Minutolo, R., Terracciano, V., Iodice, C., Giannattasio, P., Nicola, L. D., Conte, G., & Iorio, B. R. D. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.34913 · Cited by 63
Jeong, S., Cho, Y. I., Duey, M., & Rosenson, R. S. (2010) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-010-6239-7 · Cited by 62
Doyle, M. K., Rahman, M. U., Han, C., Han, J. S., Giles, J. T., Bingham, C. O., & Bathon, J. M. (2008) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2008.08.002 · Cited by 62
Analysis of drug prescription in chronic haemodialysis patients
Tozawa, M. (2002) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/17.10.1819 · Cited by 62
Quality of Life in Male Hemodialysis Patients
Türk, S., Güney, İ., Altıntepe, L., Tonbul, Z., Yıldız, A., & Yeksan, M. (2004) · Nephron Clinical Practice · doi:10.1159/000075568 · Cited by 62
Impact of Comorbidities on Mortality in Managed Care Patients With CKD
Gullion, C. M., Keith, D. S., Nichols, G. A., & Smith, D. H. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.04.083 · Cited by 62
Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients
Frank, H., Heusser, K., Höffken, B., Huber, P., Schmieder, R. E., & Schobel, H. P. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00810.x · Cited by 61
Low testosterone and anaemia in men with type 2 diabetes
Grossmann, M., Panagiotopolous, S., Sharpe, K., MacIsaac, R. J., Clarke, S., Zajac, J. D., Jerums, G., & Thomas, M. C. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03357.x · Cited by 60
Kalantar‐Zadeh, K., Streja, E., Miller, J. E., & Nissenson, A. R. (2009) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2008.12.008 · Cited by 60
Self-citationRed Blood Cell Lifespan Shortening in Patients with Early-Stage Chronic Kidney Disease
Li, J., Luo, J., Jiang, Y., Ma, Y., Ji, Y., Zhu, G., Zhou, C., Chu, H.-W., & Zhang, H. (2019) · Kidney & Blood Pressure Research · doi:10.1159/000502525 · Cited by 60
(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.35 · Cited by 60
Klopsch, C., Furlani, D., Gäbel, R., Li, W., Pittermann, E., Uğurlucan, M., Kundt, G., Zingler, C., Titze, U., Wang, W., et al. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00546.x · Cited by 60
Overview of clinical studies in hemodiafiltration: What do we need now ?
Canaud, B., Morena-Carrere, M., Leray‐Moragues, H., Chalabi, L., & Cristol, J. (2006) · Hemodialysis International · doi:10.1111/j.1542-4758.2006.01183.x · Cited by 60
Chung, E. Y. M., Palmer, S. C., Saglimbene, V. M., Craig, J. C., Tonelli, M. A., & Strippoli, G. F. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010590.pub3 · Cited by 59
Engert, A., Josting, A., Haverkamp, H., Villalobos, M., Lohri, A., Sökler, M., Zijlstra, J. M., Sturm, I., Topp, M. S., Rank, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.1835 · Cited by 59
Wang, T., Jiang, X., Lin, T., Ren, S., Li, X.-Y., Zhang, X., & Tang, Q. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.04.033 · Cited by 59
Patient satisfaction with in-centre haemodialysis care: an international survey
Palmer, S. C., Berardis, G. D., Craig, J. C., Tong, A., Tonelli, M. A., Pellegrini, F., Ruospo, M., Hegbrant, J., Wollheim, C., Celia, E., et al. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-005020 · Cited by 59
Kimmel, P. L., Cohen, S. D., & Weisbord, S. D. (2008) · Journal of Nephrology · doi:10.1093/joneph/21.s13.s54 · Cited by 59
Keithi-Reddy, S. R., Addabbo, F., Patel, T. V., Mittal, B. V., Goligorsky, M. S., & Singh, A. K. (2008) · Kidney International · doi:10.1038/ki.2008.245 · Cited by 59
Congestive Heart Failure in Patients with Chronic Kidney Disease and on Dialysis
Schreiber, B. D. (2003) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200304000-00004 · Cited by 59
Curtis, B. M., & Parfrey, P. S. (2005) · Cardiology Clinics · doi:10.1016/j.ccl.2005.04.002 · Cited by 58
Flow-Mediated Vasodilation in End-Stage Renal Disease
Verbeke, F., Pannier, B., Guérin, A. P., Boutouyrie, P., Laurent, S., & London, G. M. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01260211 · Cited by 58
New Anemia Therapies: Translating Novel Strategies From Bench to Bedside
Macdougall, I. C. (2011) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2011.11.013 · Cited by 57
Challenging the Validity of the EPO Index
Kaysen, G. A., Müller, H. G., Ding, J., & Chertow, G. M. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.09.013 · Cited by 57
Misdistribution of iron and oxidative stress in chronic kidney disease
Nakanishi, T., Kuragano, T., Nanami, M., Nagasawa, Y., & Hasuike, Y. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.06.025 · Cited by 57
Akizawa, T., Nangaku, M., Yamaguchi, T., Arai, M., Koretomo, R., Maeda, K., Miyazawa, Y., & Hirakata, H. (2019) · The Nephron journals/Nephron journals · doi:10.1159/000500487 · Cited by 57
von Drygalski, A., & Biller, J. A. (2008) · Nutrition in Clinical Practice · doi:10.1177/0884533608323426 · Cited by 57
Do AV Fistulas Contribute to Cardiac Mortality in Hemodialysis Patients?
Dikow, R., Schwenger, V., Zeier, M. G., & Ritz, E. (2002) · Seminars in Dialysis · doi:10.1046/j.1525-139x.2002.00003.x · Cited by 56
Developments in the therapeutic use of erythropoiesis stimulating agents
JELKMANN, W. E. B. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06948.x · Cited by 56
Ghali, J. K. (2009) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e328324ecec · Cited by 56
Endocrine abnormalities in chronic renal failure
Leavey, S. F., & Weitzel, W. F. (2002) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(01)00006-8 · Cited by 56
Sun, C. C., Vaja, V., Chen, S., Theurl, I., Stepanek, A. M., Brown, D. E., Cappellini, M. D., Weiss, G., Hong, C. C., Lin, H. Y.-F., et al. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs584 · Cited by 56
Reinhart, W. H. (2016) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-168032 · Cited by 57
UNRESOLVED ISSUES IN DIALYSIS: Managing Erythropoietin Hyporesponsiveness
Kwack, C., & Balakrishnan, V. S. (2006) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2006.00141.x · Cited by 56
Zelnick, L. R., Batacchi, Z. O., Ahmad, I., Dighe, A., Little, R. R., Trence, D. L., Hirsch, I. B., & de Boer, I. H. (2020) · Diabetes Care · doi:10.2337/dc20-0915 · Cited by 55
Covic, A. C., Jackson, J., Hadfield, A., Pike, J., & Siriopol, D. C. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0566-z · Cited by 55
Su, A., Alaref, S. J., Beecy, A., Min, J. K., & Karas, M. G. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.01.017 · Cited by 55
Winkelmayer, W. C., Lorenz, M., Kramar, R., Hörl, W. H., & Sunder–Plassmann, G. (2004) · American Journal of Transplantation · doi:10.1046/j.1600-6143.2004.00604.x · Cited by 55
Epoetin Alfa and Outcomes in Dialysis amid Regulatory and Payment Reform
Chertow, G. M., Liu, J., Monda, K. L., Gilbertson, D. T., Brookhart, M. A., Beaubrun, A. C., Winkelmayer, W. C., Pollock, A. S., Herzog, C. A., Ashfaq, A., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015111232 · Cited by 54
Cardiorenal syndrome type 4: From chronic kidney disease to cardiovascular impairment
Granata, A. R. M., Clementi, A., Virzì, G. M., Brocca, A., de Cal, M., Scarfia, R. V., Zanoli, L., Ronco, C., Corrao, S., & Malatino, L. (2016) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2016.02.019 · Cited by 54
Akizawa, T., Gejyo, F., Nishi, S., Iino, Y., Watanabe, Y., Suzuki, M., Saitō, A., Akiba, T., Hirakata, H., Fukuhara, S., et al. (2011) · Therapeutic Apheresis and Dialysis · doi:10.1111/j.1744-9987.2011.00931.x · Cited by 54
Correction of Anemia — Payoffs and Problems
Remuzzi, G., & Ingelfinger, J. R. (2006) · New England Journal of Medicine · doi:10.1056/nejme068233 · Cited by 54
Locatelli, F., Minutolo, R., Nicola, L. D., & Vecchio, L. D. (2022) · Drugs · doi:10.1007/s40265-022-01783-3 · Cited by 53
Erythroid-Stimulating Agents in Cancer Therapy: Potential Dangers and Biologic Mechanisms
Hadland, B., & Longmore, G. D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6945 · Cited by 53
Soluble Erythropoietin Receptor Contributes to Erythropoietin Resistance in End-Stage Renal Disease
Khankin, E. V., Mutter, W. P., Tamez, H. E., Yuan, H., Karumanchi, S. A., & Thadhani, R. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009246 · Cited by 53
Sugahara, M., Tanaka, T., & Nangaku, M. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108272 · Cited by 53
Evidence-Based Cardiology in Hemodialysis Patients
Allon, M. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013060632 · Cited by 52
DeAngelis, R. A., Reis, E. S., Ricklin, D., & Lambris, J. D. (2012) · Immunobiology · doi:10.1016/j.imbio.2012.07.012 · Cited by 52
New options for the anemia of chronic kidney disease
Coyne, D. W., Goldsmith, D. J. A., & Macdougall, I. C. (2017) · Kidney International Supplements · doi:10.1016/j.kisu.2017.09.002 · Cited by 52
Cotter, D. J., Stefanik, K., Zhang, Y., Thamer, M., Scharfstein, D. O., & Kaufman, J. S. (2004) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2004.05.002 · Cited by 52
Aapro, M., Osterwalder, B., Scherhag, A. W., & Burger, H.-U. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605255 · Cited by 52
Abbasi, M. A., Chertow, G. M., & Hall, Y. N. (2005) · PubMed Central · Cited by 51
Evidence for the Prevention and Treatment of Stroke in Dialysis Patients
Herrington, W. G., Haynes, R., Staplin, N., Emberson, J., Baigent, C., & Landray, M. (2014) · Seminars in Dialysis · doi:10.1111/sdi.12281 · Cited by 51
Long-term outcome in hemodialysis: Morbidity and mortality
Pozzoni, P., Vecchio, L. D., Pontoriero, G., Filippo, S. D., & Locatelli, F. (2004) · Journal of Nephrology · doi:10.1093/joneph/17.s8.s87 · Cited by 51
Pathophysiology of Anemia in Heart Failure
Anand, I. S. (2010) · Heart Failure Clinics · doi:10.1016/j.hfc.2010.03.002 · Cited by 50
Metadata
- Authors
- Besarab, A., Bolton, W. K., Browne, J. K., Egrie, J. C., Nissenson, A. R., Okamoto, D. M., Schwab, S. J., & Goodkin, D. A.
- Affiliations
- Henry Ford Hospital (US)
- University of Virginia Health System (US)
- Amgen (United States) (US)
- University of California, Los Angeles (US)
- Duke University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1998-08-27
- Volume
- 339
- Issue
- 9
- Pages
- 584-590
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2331665138
- Cited by
- 1,930
- References
- 28
- Citations by year
- 2026: 23 · 2025: 33 · 2024: 36 · 2023: 44 · 2022: 52 · 2021: 82 · 2020: 59 · 2019: 61 · 2018: 59 · 2017: 68 · 2016: 75 · 2015: 56 · 2014: 89 · 2013: 102 · 2012: 99
- FWCI
- 21.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Health Sciences › Medicine › Hematology › Blood transfusion and management
- Keywords
- hematocrit, recombinant human erythropoietin, epoetin, hemodialysis, end-stage renal disease, anemia, congestive heart failure, ischemic heart disease, myocardial infarction, mortality, dialysis adequacy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
